Effect of intravenous lidocaine on the ED50 of remimazolam induction dose during laryngeal mask airway insertion in adult patients

Effect of intravenous lidocaine on the ED50 of remimazolam induction dose during laryngeal mask airway insertion in adult patients: a randomized, controlled, single-blind prospective study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200063275

Enrollment

Unknown

Registered

2022-09-02

Start date

2022-09-01

Completion date

Unknown

Last updated

2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laryngeal mask for general anesthesia

Interventions

Experimental group:Lidocaine intravenous

Control group:Same volume normal saline intravenous

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years; 2. Laryngeal mask airway insertion; 3. ASA I or II; 4. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. History of allergy to local anesthetics; 2. History of allergy to benzodiazepines; 3. Long-term previous use of benzodiazepines; 4. severe arrhythmia; 5. Liver or renal dysfunctions; 6. Airway difficult; 7. Recent history of upper respiratory tract infection; 8. Other reasons that researchers believe it is not appropriate to participate in this trial.

Design outcomes

Primary

Measure	Time frame
Median effective bolus dose of remimazolam;	—

Secondary

Measure	Time frame
Nausea and vomiting;	—

Countries

China

Contacts

Public ContactWangning Shangguan

The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University

sgwning@163.com+86 13587637891

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026